8-K: InfuSystem Appoints Grant Thornton as New Auditor

InfuSystem Holdings, Inc. announced the appointment of Grant Thornton LLP as its new independent registered public accounting firm following a competitive selection process, replacing Deloitte & Touche LLP.

Summary

• InfuSystem Holdings, Inc. (the "Company") has changed its independent registered public accounting firm.
• The Audit Committee dismissed Deloitte & Touche LLP ("Deloitte") and appointed Grant Thornton LLP ("Grant Thornton").
• Grant Thornton will audit the Company's consolidated financial statements for the fiscal year ending December 31, 2026, review quarterly statements, and audit internal control over financial reporting as of December 31, 2026.
• The change followed a competitive selection process initiated by the Audit Committee.
• There were no disagreements with Deloitte on accounting principles, financial disclosures, or auditing scope during the fiscal years ended December 31, 2025 and 2024, or the subsequent interim period through March 13, 2026.
• Deloitte's audit reports for 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications.
• The Company did not consult with Grant Thornton on any accounting or auditing issues that would constitute a disagreement or reportable event prior to their appointment.
• Deloitte & Touche LLP confirmed agreement with the statements made in the 8-K filing in a letter dated March 19, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. A routine auditor change resulting from a competitive process, coupled with the explicit confirmation of no disagreements or reportable events with the outgoing auditor, indicates sound corporate governance and a lack of underlying financial issues, which is reassuring for investors.

Positives

• The change in auditor was a result of a competitive selection process, suggesting due diligence by the Audit Committee.
• There were no disagreements with the former auditor, Deloitte & Touche LLP, on any accounting principles, practices, financial statement disclosure, or auditing scope or procedure.
• Deloitte's audit reports for the fiscal years ended December 31, 2025 and 2024, contained no adverse opinion or disclaimer of opinion and were not qualified or modified.
• No reportable events were identified with the former auditor.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the scope of the auditor engagement for the fiscal year ending December 31, 2026.

Management Comments

• The Audit Committee of the Board of Directors of InfuSystem Holdings, Inc. conducted a competitive selection process to determine the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The Committee approved the dismissal of Deloitte as the Company's independent registered public accounting firm and the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm.

Industry Context

StockSavvy.ai notes that changes in independent registered public accounting firms are a routine part of corporate governance, often driven by competitive bidding processes, fee considerations, or a desire for fresh perspectives. The absence of disagreements or reportable events with the outgoing auditor, Deloitte & Touche LLP, aligns with best practices and suggests a smooth transition, which is generally viewed favorably by the market.

Comparison to Industry Standards

• StockSavvy.ai observes that the competitive selection process undertaken by InfuSystem's Audit Committee is a standard corporate governance practice. Many companies, including peers in the healthcare services and medical device sectors, periodically review their auditing relationships to ensure cost-effectiveness, quality of service, and independence.
• The explicit statement of no disagreements or reportable events with the outgoing auditor, Deloitte & Touche LLP, is a critical disclosure that meets or exceeds industry best practices for transparency during auditor transitions, contrasting with situations where such changes might signal underlying financial or accounting issues, as seen in past cases like Enron (Arthur Andersen) or more recently with certain smaller cap companies facing restatements.

Corporate Governance

Stakeholder Impact

• Shareholders: Reassurance regarding financial reporting integrity due to a transparent auditor change process with no reported disagreements or issues.
• Creditors: Potential positive signal regarding financial transparency and stability, as the auditor change was without reported issues.

Next Steps

• Grant Thornton LLP will audit InfuSystem's consolidated financial statements for the fiscal year ending December 31, 2026.
• Grant Thornton LLP will review InfuSystem's quarterly consolidated financial statements for each of the first three quarters of the fiscal year ending December 31, 2026.
• Grant Thornton LLP will audit InfuSystem's internal control over financial reporting as of December 31, 2026.

Key Dates

Recommendation

The filing details a routine change in the company's independent auditor following a competitive selection process, with explicit confirmation of no disagreements or reportable events with the outgoing firm. This indicates sound corporate governance and a healthy financial reporting environment, which is a neutral to slightly positive signal. However, this specific announcement does not provide new financial performance data or strategic shifts that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational or financial updates.

Keywords

InfuSystem Holdings, InfuSystem, INFU, auditor change, Grant Thornton, Deloitte & Touche, SEC filing, 8-K, accounting firm, financial reporting, corporate governance